Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Key Insights Revealed on the Global CD19 Antibody Market, Highlighting Growth Potential and Innovations in Cancer Therapy

      Research and Markets Logo

      News provided by

      Research and Markets

      Nov 09, 2023, 12:15 ET

      Share this article

      Share this article


      DUBLIN, Nov. 9, 2023 /PRNewswire/ -- The "Global CD19 Antibody Market & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

      The global CD19 antibody market is on track to reach a staggering value of over USD 10 billion by 2028, as revealed in the recently published "Global CD19 Antibody Market & Clinical Pipeline Outlook 2028" report. This comprehensive report provides a deep dive into the CD19 antibody market, highlighting key insights and developments in the field.

      Key Report Highlights:

      1. Market Opportunity: The global CD19 antibody market is projected to exceed USD 10 billion by 2028, showcasing its remarkable growth potential.
      2. Commercially Approved CD19 Antibodies: Currently, there are 10 approved CD19 antibodies available in the market, indicating a diverse range of treatment options for patients.
      3. Sales Insights: The report provides comprehensive annual, quarterly, and regional sales data for approved CD19 antibodies, offering valuable insights into market performance.
      4. Dosage and Price Information: Detailed information on the dosage and pricing of approved CD19 antibodies is available, helping stakeholders make informed decisions.
      5. Clinical Pipeline: There are over 190 CD19 antibodies in clinical trials, highlighting the extensive research and development efforts in this field.
      6. Clinical Trials Insights: The report offers insights into global CD19 antibodies clinical trials by company, indication, and phase, providing a comprehensive view of ongoing research.
      7. Competitive Landscape: The competitive landscape section provides insights into 30 companies actively involved in the CD19 antibody market, showcasing the dynamic nature of the industry.

      CD19-targeting therapies have emerged as a revolutionary class of immunotherapies in the past decade, capturing the attention of both the clinical and commercial spheres in the global pharmaceutical industry. Notably, the market for CD19-targeting therapies witnessed a remarkable 50% increase in 2021 and a 40% increase in 2022, attributed to rapid regulatory approvals and a promising pipeline of investigational CD19-targeting therapies.

      These therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell (CAR-T) therapies, have made a significant impact on cancer treatment. They are primarily used to treat B-cell malignancies such as non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), and large B-cell lymphoma (LBCL).

      CAR-T therapies like Kymriah and Yescarta have demonstrated remarkable clinical efficacy, leading to high response rates and prolonged remissions in patients, despite challenges such as cytokine release syndrome (CRS) and neurotoxicity, which researchers have found ways to manage.

      One key advantage of CD19-targeting therapies is their potential for long-lasting responses, significantly improving patients' quality of life. These therapies represent a significant step toward personalized medicine, tailored to each patient's unique immune system and cancer cell characteristics.

      Pharmaceutical giants like Novartis, Amgen, and Gilead have played a substantial role in the development and commercialization of CD19-targeting therapies. Smaller biotech firms, such as Viela Bio (now part of Amgen), are also making innovative contributions to the market.

      To date, nine CD19-targeting therapies have received approval from regulatory bodies, including bispecific antibodies, monoclonal antibodies, antibody-drug conjugates, and CAR-T therapies. While eight of them have FDA approvals, Carteyva has received regional approval in China, marketed by JW Therapeutics.

      The continued success of these therapies has encouraged robust research and development efforts, resulting in numerous investigational CD19-targeting therapies entering clinical trial pipelines. These therapies primarily target hematological cancers, autoimmune diseases, and disorders of the immune system.

      Regulatory bodies have been pivotal in encouraging CD19-targeting therapy development by granting special drug designations. For instance, the FDA granted Fast Track designation to candidates like KYV-101, IMPT-314, and CABA-201, developed by Kyverna Therapeutics, ImmPACT Bio, and Cabaletta Bio, respectively. The FDA's acceptance of IND applications for many candidates further underscores their potential.

      Collaborations in research and development are driving the creation of innovative CD19-targeting therapies, potentially offering advantages over approved counterparts. Proprietary platforms are being leveraged to streamline development, reducing costs and time.

      The CD19-targeting therapy market is vibrant and dynamic, driven by competition, innovation, and expanding therapeutic potential. As research explores new indications, the full therapeutic potential of CD19 protein remains to be uncovered. New market entrants are increasing competition, expected to drive innovation in this dynamic landscape.

      Key Topics Covered:

      1. Research Methodology

      2. Approved CD19 Targeting Therapies

      3. Global CD19 Antibodies Market Dynamics
      3.1 Current Market Trends & Developments
      3.2 Future Growth Avenues

      4. CD19 Targeting Therapies Clinical Trials & Market Insight by Indication
      4.1 Hematological Cancers
      4.1.1 Leukemia
      4.1.2 Lymphoma
      4.2 Solid Cancers
      4.3 Immune System Diseases

      5. CD19 Targeting Therapies Market Dynamics by Region
      5.1 US
      5.2 China
      5.3 EU
      5.4 Canada
      5.5 Australia

      6. Global CD19 Market Sales & Price insight By Approved Drugs
      6.1 Blincyto - 1st CD19 Targeting Therapy
      6.1.1 Overview & Patent Insight
      6.1.2 Pricing & Dosage Insight
      6.1.3 Sales Analysis
      6.2 Kymriah - 1st Anti-CD19 CAR T Cell Therapy
      6.2.1 Overview
      6.2.2 Pricing & Dosage Insight
      6.2.3 Sales Analysis
      6.3 Yescarta
      6.3.1 Overview & Patent Insight
      6.3.2 Pricing & Dosage
      6.3.3 Sales Analysis
      6.4 Uplizna - 1st Anti-CD19 Monoclonal Antibody
      6.4.1 Overview & Patent Insight
      6.4.2 Pricing & Dosage
      6.4.3 Sales Analysis
      6.5 Tecartus
      6.5.1 Overview
      6.5.2 Pricing & Dosage
      6.5.3 Sales Analysis
      6.6 Monjuvi
      6.6.1 Overview & Patent Insight
      6.6.2 Pricing & Dosage
      6.6.3 Sales Analysis
      6.7 Breyanzi
      6.7.1 Overview & Patent Insight
      6.7.2 Pricing & Dosage
      6.7.3 Sales Analysis
      6.8 Zynlonta - 1st CD19-Targeted ADC Therapy
      6.8.1 Overview & Patent Insight
      6.8.2 Pricing & Dosage
      6.8.3 Sales Analysis
      6.9 Carteyva
      6.9.1 Overview & Patent Insight
      6.9.2 Sales Analysis
      6.10 NexCAR19 - 1st CD19 Targeting CAR T Cell Therapy

      7. Global CD19 Antibodies Clinical Trials Overview
      7.1 By Country
      7.2 Indication
      7.3 Phase
      7.4 Therapy Class

      8. Global CD19 Antibodies Clinical Trials By Company, Indication & Phase
      8.1 Research
      8.2 Preclinical
      8.3 Phase-I
      8.4 Phase-I/II
      8.5 Phase-II
      8.6 Phase-III
      8.7 Preregistration
      8.8 Registered

      9. Commercially Approved CD19 Antibodies Clinical Insight

      10. Competitive Landscape
      10.1 AbbVie
      10.2 Aleta Biotherapeutics
      10.3 Autolus
      10.4 Bristol-Myers Squibb
      10.5 Cabaret Biotech
      10.6 Cellectis
      10.7 Cellular Biomedicine Group
      10.8 Chongqing Precision Biotech Co., Ltd
      10.9 CRISPR Therapeutics
      10.10 Eureka Therapeutics
      10.11 EXUMA Biotech
      10.12 Fate Therapeutics
      10.13 Galapagos NV
      10.14 Gilead Sciences
      10.15 Gracell Biotechnology
      10.16 Guangzhou Bio-gene Technology
      10.17 Hebei Senlang Biotechnology
      10.18 ImmPACT Bio
      10.19 Immvira Pharma
      10.20 Innovative Cellular Therapeutics
      10.21 Juventas Cell Therapy
      10.22 Kite Pharma
      10.23 Kyverna Therapeutics
      10.24 MedTherapy
      10.25 Memorial Sloan-Kettering Cancer Center
      10.26 Nanjing Bioheng Biotech
      10.27 Nanjing IASO Biotherapeutics
      10.28 Poseida Therapeutics
      10.29 Precision Biosciences
      10.30 Sana Biotechnology

      For more information about this report visit https://www.researchandmarkets.com/r/1095mf

      About ResearchAndMarkets.com
      ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected] 

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.